Anavex Life Sciences Corp. (AVXL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, CEO, Secretary & Director | 828.25k | 3.2M | 1966 |
| Ms. Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer | 194.36k | -- | 1981 |
| Dr. Walter E. Kaufmann M.D. | Chief Scientific Officer | -- | -- | -- |
| Clint Tomlinson | VP of Corporate | -- | -- | -- |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development | -- | -- | -- |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer | -- | -- | -- |
| Dr. Kun Jin Ph.D. | Head of Biostatistics | -- | -- | -- |
| Mr. David Goldberger R.Ph. | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development | -- | -- | -- |
| Dr. Juan Carlos Lopez-Talavera M.D., Ph.D. | Senior VP & Head of Research and Development | -- | -- | -- |
Anavex Life Sciences Corp.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 40
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
November 25, 2024 at 1:30 PM UTC - November 29, 2024 at 1:30 PM UTC
Anavex Life Sciences Corp. Earnings Date